julijana.stula@baselarea.swiss, Author at BaseLaunch

Looking for an experienced R&D leader to join a liver disease biotech as CSO

CSO Opportunity – Entrepreneurial R&D Leader for a Liver Disease-focused Biotech The company is seeking an entrepreneurial and experienced biopharma R&D leader to join an exciting…

julijana.stula@baselarea.swiss30.06.2026

Portfolio news

BaseLaunch Summer Get-Together 2026

Our annual summer get-together once again brought together a vibrant mix of people from across the life sciences scene in Basel and beyond. The evening…

julijana.stula@baselarea.swiss26.06.2026

Perspectives

What biotech founders need to know about investment agreements

What biotech founders need to know about investment agreements You’ve incorporated your company, secured your IP and hit a scientific milestone. Now you need capital!…

julijana.stula@baselarea.swiss24.06.2026

Perspectives

Unique insights into AbbVie’s partnering opportunities

Unique insights into AbbVie’s partnering opportunitiesAbbVie is continuously seeking partnering opportunities across therapeutics and aesthetics. As one of the most active players in global pharma,…

julijana.stula@baselarea.swiss10.06.2026

Portfolio news

Cancentus joins BaseLaunch portfolio

We’re excited to have Cancentus join our portfolio. Cancentus, a spin-off from the University of Geneva and the University of Basel, is exploiting oncogene-induced DNA…

julijana.stula@baselarea.swiss14.04.2026

Perspectives

How biotech startups can protect their IP in university licensing and industry collaborations

How biotech startups can protect their IP in licensing and industry collaborations Your science is solid, your patent is filed and the university is supportive.…

julijana.stula@baselarea.swiss10.04.2026

Perspectives

The key financial decisions and priorities for biotech startups

The key financial decisions and priorities for biotech startups At our latest webinar, Hoffmann & Partner walked founders through what financial infrastructure you actually need…

julijana.stula@baselarea.swiss31.03.2026

Portfolio news

Lonza renews partnership with BaseLaunch

Building on a strong collaboration, Lonza and BaseLaunch have renewed their partnership to further support the development of innovative therapeutics. As a Domain Partner, Lonza…

julijana.stula@baselarea.swiss30.03.2026

Portfolio news

Anaveon Appoints Thaminda Ramanayake as CEO

Basel, Switzerland, March 23, 2026 – Anaveon, a late-stage preclinical biotech focused on reprogramming the immune system with precision biologics, announces today the appointment of…

julijana.stula@baselarea.swiss24.03.2026

Portfolio news

Vossius renews partnership with BaseLaunch

We are delighted to announce that Vossius is continuing its partnership with BaseLaunch to support cutting-edge early-stage biotechs in protecting and strengthening their innovations, helping…

julijana.stula@baselarea.swiss17.03.2026

julijana.stula@baselarea.swiss

Looking for an experienced R&D leader to join a liver disease biotech as CSO

BaseLaunch Summer Get-Together 2026

What biotech founders need to know about investment agreements

Unique insights into AbbVie’s partnering opportunities

Cancentus joins BaseLaunch portfolio

How biotech startups can protect their IP in university licensing and industry collaborations

The key financial decisions and priorities for biotech startups

Lonza renews partnership with BaseLaunch

Anaveon Appoints Thaminda Ramanayake as CEO

Vossius renews partnership with BaseLaunch

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us